The drugs don't work for AstraZeneca

With its product cupboard looking increasingly bare, Britain's second-biggest drug maker may have to go shopping for growth

AstraZeneca has one dreadful headache, and nothing in its drug cabinet looks likely to make the pain go away. Yesterday, Britain's second-biggest drug maker admitted it would face a $380m (£242m) writedown this year after two of its major new drugs failed to hit targets in mid and late-stage clinical trials. The diminished prospects for its ovarian cancer drug olaparib and an experimental antidepressant named TC-5214 will, Astra admitted, damage expectations for its annual earnings, now forecast to come in at the lower end of its previous range of $7.20 to $7.40 per share.

Still, analysts had already whipped the antidepressant out of their models after its first trial failure last month, and the cancer drug was known to be high risk. So that blow was just a sniffle compared to Astra's real ailment: the pharma giant is suffering from a "patent cliff" that will see at least half of its drug sales face generic competition by 2016.

It's started already. Astra's $1.5bn-a-year cancer drug Arimidex faced generic competition for the first time last year. Blockbuster heartburn drug Nexium has already started competing with generics in Europe. It, together with Seroquel, Astra's best-selling bipolar drug, bought in combined revenues of $10.3bn last year: both will have generic competitors in the crucial, US market from 2014.

The coming months will also put Astra's cholesterol-buster Crestor, which bought in sales worth $5.7bn last year, under the spotlight. Lipitor, its Pfizer-made rival which is the world's bestselling medicine, has just come out of patent. The flood of cheap, generic alternatives is likely to hit Crestor's sales, leaving Astra with another revenue hole it needs to fill.

How will the gap be filled? There is no obvious source. Even before yesterday's double bad news, Astra's pipeline was thin. In February, it called off late-stage trials of a prostate cancer drug, zibotentan. A year ago, it wrote off $445m abandoning a new respiratory medicine for children, motavizumab.

"AstraZeneca has had two years of product failures. We're concerned," said Navid Malik, head of life science research at Merchant Securities. "The pipeline is devoid of late-stage potential blockbusters... Astra's more-established products are going generic, and the cupboard is beginning to look bare."

The drug maker has had one big success: blood thinner Brilinta launched in Europe (where it is sold as Brilique) at the end of last year, followed by the US a few months later. Analysts think it could hit sales of $1bn by 2015. But overall, despite success in emerging markets, the company's revenues are forecast to decline over the next five years.

So far, profits are holding up: in the third quarter of this year, revenues at constant currency declined 2 per cent thanks to patent expiries, but pre-tax profit was up, in part thanks to major cost-cutting [see box].

When Astra started to announce job cuts in 2008, it helped the City warm to the stocks. But this year the shine has come off. Despite more cost-cutting and the fact that drug stocks are considered a safe haven in a downturn, its shares are still down over the past year. Yesterday's news sent them lower again, off 44p to 2,905p.

The City is questioning where growth will come from next.

Its chief executive, David Brennan, almost certainly needs to go shopping, and City whispers suggest Dublin-headquartered tax exile Shire could be a target: it is expected to post double-digit revenue growth over the next few years thanks to its high-margin, highly specialised drugs.

"The business is growing very significantly," says Mr Malik. "An acquirer could take out a lot of its costs and drive revenue growth.

"Astra could be the one to do so. It needs to do something."

Bad medicine: Jobs go

This week AstraZeneca said it was axeing a quarter of its US sales staff – some 1,150 jobs – to further cut costs. That was a second wave of job losses as the drug maker, which employs 61,000 people around the world, continues its ambition to axe 10,400 jobs in the next three years. Doing so will, Astra says, save $1bn (£637m) a year. The UK has felt the pain of the job cuts too: Astra closed its research facility in Loughborough last year with the loss of 1,200 jobs. Meanwhile, it is expanding in emerging markets. In October, AstraZeneca set out plans to spend $200m in China, creating the most expensive factory it has ever built.

PROMOTED VIDEO
Arts and Entertainment
Babysitter Katie and Paul have terse words in the park
tvReview: The strength of the writing keeps viewers glued to their seats even when they are confronted with the hard-hitting scenes
News
i100
Arts and Entertainment
American singer, acclaimed actor of stage and screen, political activist and civil rights campaigner Paul Robeson (1898 - 1976), rehearses in relaxed mood at the piano.
filmSinger, actor, activist, athlete: Paul Robeson was a cultural giant. But prejudice and intolerance drove him to a miserable death. Now his story is to be told in film...
Sport
England’s opening goalscorer Alex Oxlade-Chamberlain battles with Scotland’s Charlie Mulgrew
FootballEngland must learn to keep possession and dictate games before they are exposed by the likes of Germany and Brazil
Life and Style
Make-up artists prepare contestants for last year’s Miss World, held in Budapest
fashion
Sport
Wigan Athletic’s back-of-the shirt sponsor Premier Range has pulled out due to Malky Mackay’s arrival
Football
News
ebooksNow available in paperback
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: Trainee Recruitment Consultant - Soho

£20000 - £25000 per annum + OTE £35,000: SThree: We consistently strive to be ...

Ampersand Consulting LLP: Markit EDM (CADIS) Developer

£50000 - £90000 per annum + benefits: Ampersand Consulting LLP: Markit EDM (CA...

Carlton Senior Appointments: Director, Private Bank - San Francisco, CA

$175 - $200 per annum, Benefits: full benefits: Carlton Senior Appointments: P...

Carlton Senior Appointments: San Diego, CA – Tier 1 House - Senior MD FA

Not specified: Carlton Senior Appointments: Senior MD Financial Advisor - San ...

Day In a Page

US immigration: President Obama ready to press ahead with long-promised plan to overhaul 'broken system' - but will it get past a Republican-controlled Congress?

Immigration: Obama's final frontier

The President is ready to press ahead with the long-promised plan to overhaul America's 'broken system' - but will it get past a Republican-controlled Congress?
Bill Cosby rape allegations explained: Why are these allegations coming out now? Why didn’t these women come forward earlier? And why has nobody taken legal action?

Bill Cosby rape allegations explained

Why are these allegations coming out now? Why has nobody taken legal action? And what happens next for the man once thought of as 'America's Dad'
Four years of excruciating seizures caused by the 1cm tapeworm found burrowing through a man's brain

You know that headache you’ve got?

Four years of excruciating seizures caused by the 1cm tapeworm found burrowing through a man's brain
Travelling to work by scooter is faster than walking and less sweaty than cycling, so why aren’t we all doing it?

Scoot commute

Travelling to work by scooter is faster than walking and less sweaty than cycling, so why aren’t we all doing it?
Paul Robeson: The story of how an American icon was driven to death to be told in film

The Paul Robeson story

How an American icon was driven to death to be told in film
10 best satellite navigation systems

Never get lost again: 10 best satellite navigation systems

Keep your vehicle going in the right direction with a clever device
Paul Scholes column: England must learn to keep possession and dictate games before they are exposed by the likes of Germany and Brazil

Paul Scholes column

England must learn to keep possession and dictate games before they are exposed by the likes of Germany and Brazil
Michael Dawson: I’ll thank Spurs after we win says defender as he prepares to return with Hull

Michael Dawson: I’ll thank Spurs after we win

Hull defender faces his struggling former club on Sunday ready to show what they are missing. But he says he will always be grateful to Tottenham
Frank Warren column: Dr Wu has big plans for the professionals yet he should stick to the amateur game

Frank Warren column

Dr Wu has big plans for the professionals yet he should stick to the amateur game
Synagogue attack: Fear unites both sides of Jerusalem as minister warns restoring quiet could take 'months'

Terror unites Jerusalem after synagogue attack

Rising violence and increased police patrols have left residents of all faiths looking over their shoulders
Medecins sans Frontieres: The Ebola crisis has them in the headlines, but their work goes far beyond West Africa

'How do you carry on? You have to...'

The Ebola crisis has Medecins sans Frontieres in the headlines, but their work goes far beyond West Africa
Isis extends its deadly reach with suicide bombing in Kurdish capital

Isis extends its deadly reach with suicide bombing in Kurdish capital

Residents in what was Iraq’s safest city fear an increase in jihadist attacks, reports Patrick Cockburn
Underwater photography competition winners 2014 - in pictures

'Mysterious and inviting' shot of diver wins photography competition

Stunning image of cenote in Mexico takes top prize
Sir John Major: Negative West End portrayals of politicians put people off voting

Sir John Major hits out at theatres

Negative West End portrayals of politicians put people off voting
Kicking Barbie's butt: How the growth of 3D printing enabled me to make an army of custom-made figurines

Kicking Barbie's butt

How the growth of 3D printing enabled toy-designer to make an army of custom-made figurines